1.Amawaka eedola e-COVID-19 amayeza enziwe afana nalawo aseIndiya athengiswa aphela?Jonga ngaphandle!
Kutshanje, umxholo omalunga "ne-COVID-19 amachiza enziwe afana nalawo aseIndiya athengiswe amawaka eeyuan kwibhokisi" uvele kuluhlu lokukhangela oludumileyo lwe-microblog.Amanye amachiza athengwa egameni le-China News Network, kwaye isitokhwe sasithengisiwe, ngoko ke kwakuyimfuneko ukubhukisha iveki kwangaphambili.Oogqirha bakhumbuza ukuba amachiza akufuneki athengwe ngamajelo angekho sikweni.Ukongeza, amaqela angekho emngciphekweni omkhulu akufuneki asebenzise iyeza lomlomo le-COVID-19.
Ixabiso lokuqala lebhokisi yeziyobisi yi-2300 yuan, kwaye ixabiso lokuthenga eIndiya yi-yuan eyi-1600.
“Ngoku iiodolo zibhukishwe ngokupheleleyo.”Iiarhente ezininzi zokuthenga iziyobisi zaseIndiya zixelele i-chinanews.com ukuba iPfizer COVID-19 yabo yomlomo iPaxlovid amayeza enziwe afana nalawo aveliswe ngumenzi sele ethengisiwe kutsha nje.Ukuba kuyimfuneko, banokuhlawula kuphela idiphozithi kuqala, kwaye iimpahla zingahanjiswa ngeveki ekuqaleni, okanye kwinyanga ezayo ngokukhawuleza.
Ukuba amagama athi “COVID-19 India”, “COVID-19 generic drugs” njalo njalo afakwe kwiqonga lorhwebo lwe-e-commerce, abathengi banokufumana ngokukhawuleza ulwazi lwaba arhente zokuthenga, kodwa ngokubanzi bafuna ukongeza izihlobo zeWeChat, kwaye emva koko wazise ulwazi lwempahla ethile kunye neemfuno zokuthenga.
Amachiza ePaxlovid enziwe afana nalawo aveliswe ngumenzi athengiswa zezi arhente aquka iPrimovir ekwipakethe eluhlaza kunye nePaxista ekwipakethe eluhlaza.Eyangaphambili iveliswa yi-Astrica, inkampani yaseNdiya, ngelixa le yokugqibela iveliswa ngu-Azista, i-subsidiary ye-Indian pharmaceutical enterprise hetero.Okwangoku, i-Primovir enepakethe eluhlaza iyekile ukuveliswa, kwaye yiPaxista kuphela epakishwe eluhlaza okwesibhakabhaka esathengiswayo.
Enye i-arhente yazisa ukuba ixabiso leposi yasekhaya yayiyi-1600 yuan ngebhokisi, kwaye elo le-imeyile ethe ngqo yaphesheya yayili-1200 ye-yuan ngebhokisi, i-yuan engama-400 ngexabiso eliphantsi.Ixabiso lokuthengwa kwePaxlovid eChina yi-2300 yuan ngebhokisi.
La machiza enziwe afana nalawo aveliswe ngabenzi kunzima ukuwathenga ekhoyo ngoku.Ngokutsho kokuthengwa kwe-arhente engentla, ugcino lwamkelekile, kwaye i-imeyile ethe ngqo yase-India iya kufika e-China malunga neentsuku ze-15-20.Ukwacebise ukuba umntu ngamnye athenge iibhokisi ezimbini kuphela.
Oogqirha bayakhumbuza: Kunzima ukwahlula inyaniso kubuxoki.Hlala uphaphile
Ngapha koko, iPaxlovid kudala isetyenziswa kunyango losulelo lwe-COVID-19 e-China, kodwa isetyenziswa ikakhulu kwezinye izibhedlele ezichongiweyo kwaye ifuna ukugunyaziswa kwemigqaliselo yoogqirha.Ayizizo zonke izibhedlele ezinamachiza.
Kubalulekile ukuqaphela ukuba amanye amachiza enziwe afana nalawo aveliswe ngabenzi athengiswayo ngokwekhomishini anokuthengwa ngaphandle kokunikezela ngommiselo.Kule nkalo, oogqirha abaqeqeshiweyo bakhumbuza wonke umntu ukuba aqaphele.
“Singoogqirha abaqeqeshiweyo, asikukhuthazi ukuthenga oomatshini bokulinganisa abavela kwamanye amazwe, kuba kunzima ukuxela okuyinyani kubuxoki.”UZhang Jiming, usekela mlawuli weZiko leSizwe lezoNyango lweZifo ezosulelayo kunye nogqirha oyintloko, unjingalwazi kunye nomphathi wesibhedlele sase-Huashan esinxulumana neYunivesithi yaseFudan, uxelele i-chinanews.com ukuba ezinye zezigulana azenze udliwano-ndlebe okanye iintsapho zabo zathenga oko kufana ngasese, kwaye babenexhala lokuba bathenga iziyobisi zomgunyathi.Uthe kwakunzima ukuqinisekisa umgangatho wamachiza enziwe afana nalawo aveliswe ngabenzi asuka kwimvelaphi kunye neemeko zokugcinwa kwamachiza xa kuthengwa amachiza enziwe afana nalawo aveliswe ngabenzi kumazwe angaphandle.
UZhang Jiming wazisa ukuba iyeza lomlomo le-COVID-19 lisetyenziswa ikakhulu kumaqela asemngciphekweni omkhulu wokuthintela izifo eziqatha, kwaye linokusebenza kuphela xa lisetyenziswe kwangoko.Amaqela angekho sengozini akufuneki angxamele ukuthenga, kwaye ukusetyenziswa kakubi kunokubangela ukuxhathisa kumachiza.Ayiyomfuneko nangokweklinikhi, kuba uninzi lwezigulana azibonakali okanye zithambile, kwaye isifo sinokuphela.
Uxelele i-chinanews.com ukuba, ngokwemeko yaseShanghai, izibhedlele ezinkulu, izibhedlele ezichongiweyo ze-COVID-19 kunye namanye amaziko ezonyango ngokubanzi anenani elithile lamachiza e-anti-COVID-19, asetyenziswa ngamaqela asemngciphekweni omkhulu ahlangabezana nemiqondiso kwaye bosulelwe yi-COVID-19, ukuze kuthintelwe isifo esiqatha kunye nokunciphisa izinga lokusweleka.
Ukongeza, ngokweengxelo zemithombo yeendaba, abasebenzi bezomthetho bakhumbuza ukuba amachiza e-India e-COVID-19 athengiswa kwi-Intanethi awakavunywa eTshayina.Phantsi koMthetho okhoyo ngoku woLawulo lweZiyobisi weRiphabhliki Yabantu baseTshayina, nangona iziyobisi ezidweliswe kumazwe angaphandle kodwa zingekavunywa eTshayina zingasachongwa nje njengeziyobisi zomgunyathi, abo bazisebenzisayo basaza kujongana nezohlwayo zolawulo lokungeniswa kweziyobisi ngaphandle kwemvume ngokungekho mthethweni.
2. Xinlitai umkile!Ukubamba iintlobo ezimbini zeebhiliyoni zeebhiliyoni, iindidi ezili-11 zamachiza amatsha oMdidi woku-1.
Kutshanje, umbhobho we-Xinlitai R&D wenze inkqubela entsha.Ichiza elitsha le-SAL0133 tablets lisetyenziselwe ukusetyenziswa eklinikhi.Iziphumo zohlalutyo lweenkcukacha-manani zangaphambili zifunyenwe kwiSigaba se-Ib solingo lwezonyango lwe-PCSK9 ye-monoclonal antibody.Ukusukela ngo-2022, i-Xinlitai ifake isicelo se-IND/NDA ye-7 yeziyobisi ezintsha, kwaye uphando olutsha kunye nophuhliso luye lwakhuthazwa ngokuthe ngcembe.Okwangoku, i-Xinlitai ineentlobo ezimbini zenqanaba le-1 yebhiliyoni, i-22 yazo iye yavavanywa (i-8 yeyokuqala);Amachiza amatsha angama-21 aphantsi kophando, i-6 kuwo akwinqanaba leklinikhi le-NDA okanye iSigaba sesi-III, kwaye umbhobho wokusungula ungenile kwixesha lokufumana imali.
Imbonakalo ebanzi ye-COVID-19 iyeza loMlomo liyabonakala!I-Xinlitai ingena kwiSekethe ye-COVID-19
NgoDisemba 20, u-Xinlitai ubhengeze ukuba isicelo seklinikhi ye-SAL0133, i-molecule encinci yeyeza elitsha eliphuhliswe ngokuzimeleyo yinkampani, yamkelwa yi-State Food and Drug Administration.I-SAL0133 sisixhobo esinamandla, esibanzi esichasene ne-coronavirus 3CL protease (3CLpro) inhibitor eyenziwe yasungulwa ngokuzimeleyo yaphuhliswa yinkampani enamalungelo azimeleyo epropathi enomgangatho ophezulu wokuqonda.Okwangoku, uphawu lweklinikhi oluza kuphuhliswa kukunyanga inyumoniya yabantu abadala ephakathi/eqhelekileyo ye-coronavirus (COVID-19).
I-3CLpro idlala indima ebalulekileyo ekuphindaphindweni kwe-RNA ye-coronavirus yenoveli, ngakumbi kwinqanaba lokuqala lokuphindaphinda emva kokuba intsholongwane ingene kwiseli yomkhosi, inqanda umsebenzi we-3CLpro protease, enokuthintela ngokufanelekileyo ukuphindaphinda kwentsholongwane kwaye ifezekise indima ye-coronavirus yenoveli.
I-SAL0133 inendlela ecacileyo yokwenza, kwaye inesiphumo esomeleleyo, esibanzi esichasene ne-COVID-19.Kulindeleke ukuba akufuneki ukudibanisa ne-CYP3A4 inhibitor ritonavir, kwaye ingozi enokwenzeka yokusebenzisana kweziyobisi iphantsi;Kulindeleke ukuba kuphunyezwe ukusetyenziswa kwechiza elinye leklinikhi kanye ngemini kunye nokuphucula ukuthotyelwa kwamayeza esigulane.Ukuba inokuphuhliswa ngempumelelo kwaye ivunywe ukuba ithengiswe, iya kunika izigulane ukhetho olutsha lwamachiza ukuhlangabezana neemfuno zeklinikhi ezingafezekanga.
Uphando kunye nophuhliso lwe-3CL ekujoliswe kuyo kwi-anti-COVID-19 yomlomo yamachiza emolekyuli encinci itsale umdla obanzi.Okwangoku, yiPfizer's Paxlovid kuphela evunyiweyo ukuba ithengiswe kwihlabathi.Ngaphezulu kwe-10 lamashishini amayeza asekhaya kunye namaziko ophando lwenzululwazi aqhube uphando kunye nophuhliso lwe-3CL ekujoliswe kuyo amachiza e-COVID-19, kubandakanywa i-FB2001 ye-Frontier Biology, i-VV993 ye-Junshi Biology/Wangshan Wangshui, i-SIM0417 ye-Pioneer Pharmaceutical, i-RAY1216 ye-Pharmaceutical tablets I-GST-HG171 yaseGuangshengtang, njl.
Ngeentlobo ezi-2 eziphambili ze-1 yeebhiliyoni ezisesandleni, amayeza amatsha asi-7 kulo nyaka amkela inkqubela entsha
Ngasekupheleni kuka-2022, njengommeli oqhelekileyo wenguqu ye-R&D kwishishini lamayeza, i-Xinlitai ifumene ngempumelelo indlela yayo yophuhliso phantsi koxinzelelo kunye nohlengahlengiso.
Kwiikota ezintathu zokuqala zika-2022, ingeniso yenkampani yayizibhiliyoni ezi-2.548 zeeyuan, ngokukhula konyaka-ngonyaka nge-16.5%, kwaye inzuzo yayo yayizizigidi ezingama-539 zeeyuan, ukukhula konyaka-ngonyaka ngama-37.64%.Ukusebenza kakuhle kwabeka isiseko esiluqilima sophuhliso olulandelayo.Inkampani ilindele ukuba ngo-2022, iTaijia (icwecwe ze-clopidogrel bisulfate) izakufumana malunga nebhiliyoni enye yeeyuan, kwaye iSinritan (ipilisi zealisartan) izakufumana malunga ne-900 yezigidi zeeyuan ukuya kwibhiliyoni enye yeyuan.Inkampani ineentlobo ezingama-22, ezisi-8 kuzo zezokuqala eTshayina.
Ngo-2019, olona luhlu luphambili lweXinlitai, eTaijia, yaphulukana nebhidi yayo ekuthengeni okuphakathi kwe-4 + 7, nto leyo eyanyanzela uXinlitai ukuba enze utshintsho.Kwingxelo yonyaka ka-2019, uXinlitai ubhengeze ukuba "umbhobho wophando uza kulungiswa ngobuchule, kwaye iiprojekthi ze-analog yebhayoloji ye-anti-tumor kunye ne-antibiotic kwezinye izigaba zeklinikhi ziya kupheliswa".Kwi-2020, ukwenzela ukunyusa ngakumbi umbhobho phantsi kophando kunye nokugxila kwi-R & D kunye nokukhuthazwa kweemveliso ezintsha, i-Xinlitai idlulisele amalungelo afanelekileyo kunye nomdla we-dapoxetine hydrochloride, i-erlotinib hydrochloride, i-rivasaban kunye nezinye iiprojekthi, kwaye yafumana imali yokudluliselwa.
Emva kohlengahlengiso oluthile, okwangoku, umbhobho wamachiza enziwe afana nalawo eXinritai kuphela unesicelo sokuthengisa soMgangatho wesi-4 wokuxelisa amacwecwe e-sodium ye-Sakubatrovalsartan ephantsi koqwalaselo, kunye nesicelo esongezelelweyo sovavanyo lokungaguquguquki kwe-cefuroxime sodium yokutofwa kunye ne-cefotaxime yesodium yenaliti ephantsi koqwalaselo.Kufanelekile ukukhankanya ukuba ukusukela ngoJulayi ka-2019, uXinlitai akazange afake isicelo samachiza amatsha enziwe afana nalawo aveliswe ngumenzi ngaphezulu kweminyaka emi-3, kwaye wagxila ngakumbi kubuchule obutsha nakuphando.
Ukusukela ngo-2022, u-Xinlitai wenze inkqubela phambili eqhubekayo kuphando kunye nophuhliso lwamachiza amatsha.Ngomhla we-4 kaJanuwari 2022, ukusetyenziswa koluhlu lweCINRITAI yeHIF-PHI inhibitor tablets Enasitar yenziwa yiCDE;Emva koko, iNkampani ingenise izicelo zeklinikhi zamachiza amatsha amahlanu eKlasi 1, ezizezi, i-recombinant human neuromodulin-1 anti HER3 antibody fusion protein injection, SAL0112 tablets, SAL008 injection, SAL0119 tablets and SAL0133 tablets;Ngomhla we-3 kaNovemba, iklasi entsha ye-2.3 iphuculwe i-alisartan yeziyobisi kunye neepilisi ze-amlodipine ze-SINRITAI zingenise isicelo soluhlu, okulindeleke ukuba yenze i-synergy yeqhinga kunye neklasi eluhlu lwe-1.1 ye-antihypertensive drug SINRITAI.
JinDun Medicalinentsebenziswano yexesha elide yophando lwezenzululwazi kunye neteknoloji yokuxhunyelelwa kwiiyunivesithi zaseTshayina.Ngezixhobo zonyango ezityebileyo zikaJiangsu, inobudlelwane bexesha elide kunye neIndiya, iSoutheast Asia, iSouth Korea, iJapan kunye nezinye iimarike.Ikwabonelela ngeenkonzo zentengiso kunye nentengiso kuyo yonke inkqubo ukusuka phakathi ukuya kwimveliso egqityiweyo ye-API.Sebenzisa izibonelelo eziqokelelweyo zeYangshi Chemical kwichemistry fluorine ukubonelela ngeenkonzo ezizodwa zokwenza imichiza kumaqabane.Ukubonelela ngenkqubo yokuveliswa kwezinto ezintsha kunye neenkonzo zophando lokungcola kubathengi abajoliswe kuyo.
I-JinDun Medical igxininisa ekudaleni iqela elinamaphupha, ukwenza iimveliso ngesidima, ubuqili, ubukhali, kwaye uphume wonke ube liqabane elithembekileyo kunye nomhlobo wabathengi! Ababoneleli besisombululo esisodwa, i-R&D elungiselelweyo kunye neenkonzo zemveliso ezilungiselelwe abaphakathi bamayeza kunye nee-APIs, yobuchwepheshaimveliso yamayeza elungiselelweyo(CMO) kunye nababoneleli ngeenkonzo zeR&D kunye nemveliso (CDMO).UJindun uya kukukhapha ukuya kuchitha i-COVID-19.
Ixesha lokuposa: Jan-28-2023